Sutro Biopharma (STRO) Cash from Investing Activities (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Cash from Investing Activities data on file, last reported at $18.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Investing Activities fell 78.62% year-over-year to $18.7 million; the trailing twelve-month figure through Dec 2025 stood at $45.0 million (down 79.4% YoY), and the FY2025 full-year result was $45.0 million, down 79.4% from the prior year.
• Cash from Investing Activities fell to $18.7 million in Q4 2025, from $40.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $147.3 million in Q3 2024 to a low of -$121.7 million in Q1 2021.
• A 5-year average of $6.4 million and a median of $12.3 million in 2021 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 715.44% in 2022, while the deepest fall reached 3380.69% in 2022.
• Tracing STRO's Cash from Investing Activities over 5 years: stood at $20.8 million in 2021, then tumbled by 282.29% to -$37.9 million in 2022, then jumped by 37.93% to -$23.5 million in 2023, then jumped by 472.08% to $87.5 million in 2024, then tumbled by 78.62% to $18.7 million in 2025.
• Business Quant data shows STRO's Cash from Investing Activities at $18.7 million in Q4 2025, $40.0 million in Q3 2025, and $2.6 million in Q2 2025.